Prospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 28, 2020; 26(32): 4878-4888
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4878
Table 1 Screening results of hepatitis C virus-positive patients
Patient IDOraQuick®anti-HCVAnti-HCV levels
84Positive
195Positive
263PositivePositive11 <
267PositivePositive11 <
333Positive
348PositivePositive11 <
373PositivePositive11 <
374PositivePositive11 <
410PositivePositive11 <
413NegativePositive1.35
422NegativePositive9.67
424PositivePositive11 <
426Positive
428PositivePositive11 <
435Positive
490Positive11 <
515Positive11 <
Table 2 Patient characteristics
HCV negative (% of patients, n = 524)HCV positive (% of patients, n = 17)P value
Males5293.80.001
Born in the former USSR77.947.10.003
PWID1.182.4< 0.001
Served time in prison8.664.7< 0.001
HIV1.723.5< 0.001
MSM8.40.00.212
Received blood products prior to 19928.40.00.213
Mother with HCV infection2.10.00.546
Received organ transplant prior to 19920.20.00.857
Chronic kidney disease7.15.90.85
Table 3 Multivariate analysis of risk factors for hepatitis C virus
Univariate logistic regression
Multivariate logistic regression
VariableExp (b)95%CIP valueExp (b)95%CIP value
Gender (female vs male)0.0720.009-0.550.0110.5780.043-7.710.679
PWID (yes vs no)402.88991.3-1777.1< 0.001188.9533.88-1053.82< 0.001
Served time in prison (yes vs no)19.5156.89-55.25< 0.0014.0760.623-26.670.143
HIV (yes vs no)17.64.8-64.6< 0.0015.320.242-116.780.289
Born in the former USSR (yes vs no)0.250.09-0.670.0060.5620.092-3.420.532